Nepafenac 0.1% Sterile Ophthalmic Suspension: It is indicated for the treatment of postoperative ocular pain and inflammation, including after cataract surgery. It is also used for inhibition of surgery-induced miosis and prevention of postoperative cystoid macular edema (CME).

Nepafenac 0.3% Sterile Ophthalmic Suspension: It is indicated for the treatment of postoperative pain and inflammation associated with cataract surgery.

Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) prodrug. After ocular administration, it penetrates the cornea and is converted by ocular tissue hydrolase into its active form, Amfenac, a potent NSAID. Amfenac inhibits cyclooxygenase (COX) enzyme activity, which is required for prostaglandin synthesis, thereby reducing inflammation and pain.

Nepafenac 0.1% Sterile Ophthalmic Suspension

• For post-operative pain & inflammation: Instill 1 drop 3 times daily 1 day prior to cataract surgery and continued on the day of surgery and through the first 2 weeks of the post-operative period.
• For surgery induced miosis: Instill 1 drop 3 times daily 1 day before surgery & on the day of surgery.
• For prevention of post-operative CME: Instill 1 drop 3 times daily 1 day before surgery and continued on the day of surgery and through the first 6 weeks of the post-operative period.

Nepafenac 0.3% Sterile Ophthalmic Suspension

• For post-operative pain & inflammation: Instill 1 drop once daily 1 day prior to cataract surgery and continued on the day of surgery and through the first 2 weeks of the post-operative period. An additional drop should be administered 30 to 120 minutes prior to surgery.

This medicine is contraindicated in patients with known hypersensitivity to Nepafenac, any of the formulation ingredients, or other NSAIDs.

Reported side effects include foreign body sensation, eyelid margin crusting, ocular discomfort, and ocular hyperemia.

Use in pregnancy: There are no adequate and well-controlled studies in pregnant women. Nepafenac should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.

Use in lactation: It is not known whether this drug is excreted in human milk. Therefore, caution should be exercised when administering Nepafenac ophthalmic suspension to nursing mothers.

Nepafenac should be used with caution in patients with bleeding tendencies or those receiving drugs that may prolong bleeding time.

Use in children: Safety and effectiveness in patients below 18 years have not been established.
Use in elderly: No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Ophthalmic Non-Steroidal drugs